Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2 signaling pathway, and the molecular mechanisms related t
Tumor incisional biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the TRastuzumab-UPfront-in-HER2-positive-locally-advanced- BC (TRUP)
AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with p
.rda file for Seurat object of scRNA-seq data from BT474 breast cancer cell lines treated with DMSO, Neratinib, Fulvestrant, and a combination of Neratinib and Fulvestrant.
